Pay in 4 interest-free payments of $6.18 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Add two strength days each week and 7,000-9,000 steps daily
Retatrutide (LY3437943) is a synthetic peptide investigated in preclinical and phase 2 research models as a triple agonist of GLP-1, GIP, and glucagon receptors
Interestingly, stroke reduction reached statistical significance only in patients with diabetes (35% reduction, relative risk 0.65), suggesting potential differences in mechanism or baseline risk profiles between diabetic and non-diabetic populations
These effects stop when the drug is discontinued
US$ 21.23
US$ 21.59
US$ 26.68
US$ 24.06
US$ 27.68
US$ 28.19
